Control of Metastasis by NK Cells

Cancer Cell

Volumn 32, Issue 2, 2017, Pages 135-154

  López Soto, Alejandro ^a   Gonzalez, Segundo ^a   Smyth, Mark J ^b   Galluzzi, Lorenzo ^c,d  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

ADCC; circulating tumor cells; CTLA4; disseminated tumor cells; DNAM 1; immune checkpoint blockers; metastatic cascade; NKG2D; PD 1; TGFB1

Indexed keywords

ANTIMETASTATIC AGENT;

CANCER CELL; CANCER CONTROL; CANCER IMMUNOTHERAPY; HUMAN; IMMUNOSURVEILLANCE; METASTASIS; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; REVIEW; ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; NEOPLASM METASTASIS; NEOPLASMS; PATHOLOGY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ANIMALS; HUMANS; IMMUNOLOGIC SURVEILLANCE; IMMUNOTHERAPY; KILLER CELLS, NATURAL; NEOPLASM METASTASIS; NEOPLASMS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 85029549369     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2017.06.009     Document Type: Review

References (203)

1. Ali, T.H., Pisanti, S., Ciaglia, E., Mortarini, R., Anichini, A., Garofalo, C., Tallerico, R., Santinami, M., Gulletta, E., Ietto, C., et al. Enrichment of CD56(dim)KIR+CD57+ highly cytotoxic NK cells in tumour-infiltrated lymph nodes of melanoma patients. Nat. Commun., 5, 2014, 5639.
2. Ames, E., Canter, R.J., Grossenbacher, S.K., Mac, S., Chen, M., Smith, R.C., Hagino, T., Perez-Cunningham, J., Sckisel, G.D., Urayama, S., et al. NK cells preferentially target tumor cells with a cancer stem cell phenotype. J. Immunol. 195 (2015), 4010–4019.
3. Andrews, D.M., Estcourt, M.J., Andoniou, C.E., Wikstrom, M.E., Khong, A., Voigt, V., Fleming, P., Tabarias, H., Hill, G.R., van der Most, R.G., et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J. Exp. Med. 207 (2010), 1333–1343.
4. Aranda, F., Buque, A., Bloy, N., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W.H., Fucikova, J., Galon, J., Spisek, R., et al. Trial watch: adoptive cell transfer for oncological indications. Oncoimmunology, 4, 2015, e1046673.
5. Armeanu, S., Bitzer, M., Lauer, U.M., Venturelli, S., Pathil, A., Krusch, M., Kaiser, S., Jobst, J., Smirnow, I., Wagner, A., et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res. 65 (2005), 6321–6329.
6. Avgustinova, A., Iravani, M., Robertson, D., Fearns, A., Gao, Q., Klingbeil, P., Hanby, A.M., Speirs, V., Sahai, E., Calvo, F., Isacke, C.M., Tumour cell-derived Wnt7a recruits and activates fibroblasts to promote tumour aggressiveness. Nat. Commun., 7, 2016, 10305.
7. Baginska, J., Viry, E., Berchem, G., Poli, A., Noman, M.Z., van Moer, K., Medves, S., Zimmer, J., Oudin, A., Niclou, S.P., et al. Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia. Proc. Natl. Acad. Sci. USA 110 (2013), 17450–17455.
8. Barber, M.A., Zhang, T., Gagne, B.A., Sentman, C.L., NK cells negatively regulate antigen presentation and tumor-specific CTLs in a syngeneic lymphoma model. J. Immunol. 178 (2007), 6140–6147.
9. Beavis, P.A., Divisekera, U., Paget, C., Chow, M.T., John, L.B., Devaud, C., Dwyer, K., Stagg, J., Smyth, M.J., Darcy, P.K., Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors. Proc. Natl. Acad. Sci. USA 110 (2013), 14711–14716.
10. Benson, D.M. Jr., Bakan, C.E., Mishra, A., Hofmeister, C.C., Efebera, Y., Becknell, B., Baiocchi, R.A., Zhang, J., Yu, J., Smith, M.K., et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood 116 (2010), 2286–2294.
11. Benson, D.M. Jr., Bakan, C.E., Zhang, S., Collins, S.M., Liang, J., Srivastava, S., Hofmeister, C.C., Efebera, Y., Andre, P., Romagne, F., et al. IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect. Blood 118 (2011), 6387–6391.
12. Benson, D.M. Jr., Cohen, A.D., Jagannath, S., Munshi, N.C., Spitzer, G., Hofmeister, C.C., Efebera, Y.A., Andre, P., Zerbib, R., Caligiuri, M.A., A phase I trial of the anti-KIR antibody IPH2101 and lenalidomide in patients with relapsed/refractory multiple myeloma. Clin. Cancer Res. 21 (2015), 4055–4061.
13. Benson, D.M. Jr., Hofmeister, C.C., Padmanabhan, S., Suvannasankha, A., Jagannath, S., Abonour, R., Bakan, C., Andre, P., Efebera, Y., Tiollier, J., et al. A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma. Blood 120 (2012), 4324–4333.
14. Berchem, G., Noman, M.Z., Bosseler, M., Paggetti, J., Baconnais, S., Le Cam, E., Nanbakhsh, A., Moussay, E., Mami-Chouaib, F., Janji, B., Chouaib, S., Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-beta and miR23a transfer. Oncoimmunology, 5, 2016, e1062968.
15. Best, M.G., Sol, N., Kooi, I., Tannous, J., Westerman, B.A., Rustenburg, F., Schellen, P., Verschueren, H., Post, E., Koster, J., et al. RNA-seq of tumor-educated platelets enables blood-based pan-cancer, multiclass, and molecular pathway cancer diagnostics. Cancer Cell 28 (2015), 666–676.
16. Bidwell, B.N., Slaney, C.Y., Withana, N.P., Forster, S., Cao, Y., Loi, S., Andrews, D., Mikeska, T., Mangan, N.E., Samarajiwa, S.A., et al. Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape. Nat. Med. 18 (2012), 1224–1231.
17. Blake, S.J., Stannard, K., Liu, J., Allen, S., Yong, M.C., Mittal, D., Aguilera, A.R., Miles, J.J., Lutzky, V.P., de Andrade, L.F., et al. Suppression of metastases using a new lymphocyte checkpoint target for cancer immunotherapy. Cancer Discov. 6 (2016), 446–459.
18. Boire, A., Zou, Y., Shieh, J., Macalinao, D.G., Pentsova, E., Massague, J., Complement component 3 adapts the cerebrospinal fluid for leptomeningeal metastasis. Cell 168 (2017), 1101–1113.e13.
19. Bos, P.D., Zhang, X.H., Nadal, C., Shu, W., Gomis, R.R., Nguyen, D.X., Minn, A.J., van de Vijver, M.J., Gerald, W.L., Foekens, J.A., Massague, J., Genes that mediate breast cancer metastasis to the brain. Nature 459 (2009), 1005–1009.
20. Bottos, A., Gotthardt, D., Gill, J.W., Gattelli, A., Frei, A., Tzankov, A., Sexl, V., Wodnar-Filipowicz, A., Hynes, N.E., Decreased NK-cell tumour immunosurveillance consequent to JAK inhibition enhances metastasis in breast cancer models. Nat. Commun., 7, 2016, 12258.
21. Briercheck, E.L., Trotta, R., Chen, L., Hartlage, A.S., Cole, J.P., Cole, T.D., Mao, C., Banerjee, P.P., Hsu, H.T., Mace, E.M., et al. PTEN is a negative regulator of NK cell cytolytic function. J. Immunol. 194 (2015), 1832–1840.
22. Britschgi, A., Andraos, R., Brinkhaus, H., Klebba, I., Romanet, V., Muller, U., Murakami, M., Radimerski, T., Bentires-Alj, M., JAK2/STAT5 inhibition circumvents resistance to PI3K/mTOR blockade: a rationale for cotargeting these pathways in metastatic breast cancer. Cancer Cell 22 (2012), 796–811.
23. Bruno, A., Focaccetti, C., Pagani, A., Imperatori, A.S., Spagnoletti, M., Rotolo, N., Cantelmo, A.R., Franzi, F., Capella, C., Ferlazzo, G., et al. The proangiogenic phenotype of natural killer cells in patients with non-small cell lung cancer. Neoplasia 15 (2013), 133–142.
24. Buque, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A., Cremer, I., Fridman, W.H., Fucikova, J., Galon, J., Marabelle, A., et al. Trial Watch: immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology, 4, 2015, e1008814.
25. Buque, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A., Fridman, W.H., Fucikova, J., Galon, J., Spisek, R., Tartour, E., et al. Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy. Oncoimmunology, 5, 2016, e1149674.
26. Carlsten, M., Korde, N., Kotecha, R., Reger, R., Bor, S., Kazandjian, D., Landgren, O., Childs, R.W., Checkpoint inhibition of KIR2D with the monoclonal antibody IPH2101 induces contraction and hyporesponsiveness of NK cells in patients with myeloma. Clin. Cancer Res. 22 (2016), 5211–5222.
27. Carosella, E.D., Rouas-Freiss, N., Tronik-Le Roux, D., Moreau, P., LeMaoult, J., HLA-G: an immune checkpoint molecule. Adv. Immunol. 127 (2015), 33–144.
28. Castriconi, R., Daga, A., Dondero, A., Zona, G., Poliani, P.L., Melotti, A., Griffero, F., Marubbi, D., Spaziante, R., Bellora, F., et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 182 (2009), 3530–3539.
29. Cekic, C., Day, Y.J., Sag, D., Linden, J., Myeloid expression of adenosine A2A receptor suppresses T and NK cell responses in the solid tumor microenvironment. Cancer Res. 74 (2014), 7250–7259.
30. Cerwenka, A., Lanier, L.L., Natural killer cell memory in infection, inflammation and cancer. Nat. Rev. Immunol. 16 (2016), 112–123.
31. Chan, C.J., Andrews, D.M., McLaughlin, N.M., Yagita, H., Gilfillan, S., Colonna, M., Smyth, M.J., DNAM-1/CD155 interactions promote cytokine and NK cell-mediated suppression of poorly immunogenic melanoma metastases. J. Immunol. 184 (2010), 902–911.
32. Chan, C.J., Martinet, L., Gilfillan, S., Souza-Fonseca-Guimaraes, F., Chow, M.T., Town, L., Ritchie, D.S., Colonna, M., Andrews, D.M., Smyth, M.J., The receptors CD96 and CD226 oppose each other in the regulation of natural killer cell functions. Nat. Immunol. 15 (2014), 431–438.
33. Chitadze, G., Lettau, M., Bhat, J., Wesch, D., Steinle, A., Furst, D., Mytilineos, J., Kalthoff, H., Janssen, O., Oberg, H.H., Kabelitz, D., Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the “a disintegrin and metalloproteases” 10 and 17. Int. J. Cancer 133 (2013), 1557–1566.
34. Chow, M.T., Sceneay, J., Paget, C., Wong, C.S., Duret, H., Tschopp, J., Moller, A., Smyth, M.J., NLRP3 suppresses NK cell-mediated responses to carcinogen-induced tumors and metastases. Cancer Res. 72 (2012), 5721–5732.
35. Coca, S., Perez-Piqueras, J., Martinez, D., Colmenarejo, A., Saez, M.A., Vallejo, C., Martos, J.A., Moreno, M., The prognostic significance of intratumoral natural killer cells in patients with colorectal carcinoma. Cancer 79 (1997), 2320–2328.
36. Conlon, K.C., Lugli, E., Welles, H.C., Rosenberg, S.A., Fojo, A.T., Morris, J.C., Fleisher, T.A., Dubois, S.P., Perera, L.P., Stewart, D.M., et al. Redistribution, hyperproliferation, activation of natural killer cells and CD8 T cells, and cytokine production during first-in-human clinical trial of recombinant human interleukin-15 in patients with cancer. J. Clin. Oncol. 33 (2015), 74–82.
37. Crome, S.Q., Nguyen, L.T., Lopez-Verges, S., Yang, S.Y., Martin, B., Yam, J.Y., Johnson, D.J., Nie, J., Pniak, M., Yen, P.H., et al. A distinct innate lymphoid cell population regulates tumor-associated T cells. Nat. Med. 23 (2017), 368–375.
38. Delahaye, N.F., Rusakiewicz, S., Martins, I., Menard, C., Roux, S., Lyonnet, L., Paul, P., Sarabi, M., Chaput, N., Semeraro, M., et al. Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat. Med. 17 (2011), 700–707.
39. Delconte, R.B., Kolesnik, T.B., Dagley, L.F., Rautela, J., Shi, W., Putz, E.M., Stannard, K., Zhang, J.G., Teh, C., Firth, M., et al. CIS is a potent checkpoint in NK cell-mediated tumor immunity. Nat. Immunol. 17 (2016), 816–824.
40. Della Chiesa, M., Carlomagno, S., Frumento, G., Balsamo, M., Cantoni, C., Conte, R., Moretta, L., Moretta, A., Vitale, M., The tryptophan catabolite L-kynurenine inhibits the surface expression of NKp46- and NKG2D-activating receptors and regulates NK-cell function. Blood 108 (2006), 4118–4125.
41. Deng, W., Gowen, B.G., Zhang, L., Wang, L., Lau, S., Iannello, A., Xu, J., Rovis, T.L., Xiong, N., Raulet, D.H., Antitumor immunity. A shed NKG2D ligand that promotes natural killer cell activation and tumor rejection. Science 348 (2015), 136–139.
42. Diefenbach, A., Jensen, E.R., Jamieson, A.M., Raulet, D.H., Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature 413 (2001), 165–171.
43. Donskov, F., von der Maase, H., Impact of immune parameters on long-term survival in metastatic renal cell carcinoma. J. Clin. Oncol. 24 (2006), 1997–2005.
44. Dunn, G.P., Ikeda, H., Bruce, A.T., Koebel, C., Uppaluri, R., Bui, J., Chan, R., Diamond, M., White, J.M., Sheehan, K.C., Schreiber, R.D., Interferon-gamma and cancer immunoediting. Immunol. Res. 32 (2005), 231–245.
45. Dupaul-Chicoine, J., Arabzadeh, A., Dagenais, M., Douglas, T., Champagne, C., Morizot, A., Rodrigue-Gervais, I.G., Breton, V., Colpitts, S.L., Beauchemin, N., Saleh, M., The Nlrp3 inflammasome suppresses colorectal cancer metastatic growth in the liver by promoting natural killer cell tumoricidal activity. Immunity 43 (2015), 751–763.
46. Eckelhart, E., Warsch, W., Zebedin, E., Simma, O., Stoiber, D., Kolbe, T., Rulicke, T., Mueller, M., Casanova, E., Sexl, V., A novel Ncr1-Cre mouse reveals the essential role of STAT5 for NK-cell survival and development. Blood 117 (2011), 1565–1573.
47. Erler, J.T., Bennewith, K.L., Nicolau, M., Dornhofer, N., Kong, C., Le, Q.T., Chi, J.T., Jeffrey, S.S., Giaccia, A.J., Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440 (2006), 1222–1226.
48. Ferlazzo, G., Moretta, L., Dendritic cell editing by natural killer cells. Crit. Rev. Oncog. 19 (2014), 67–75.
49. Fernandez, N.C., Lozier, A., Flament, C., Ricciardi-Castagnoli, P., Bellet, D., Suter, M., Perricaudet, M., Tursz, T., Maraskovsky, E., Zitvogel, L., Dendritic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nat. Med. 5 (1999), 405–411.
50. Ferrari de Andrade, L., Ngiow, S.F., Stannard, K., Rusakiewicz, S., Kalimutho, M., Khanna, K.K., Tey, S.K., Takeda, K., Zitvogel, L., Martinet, L., Smyth, M.J., Natural killer cells are essential for the ability of BRAF inhibitors to control BRAFV600E-mutant metastatic melanoma. Cancer Res. 74 (2014), 7298–7308.
51. Fischer, K.R., Durrans, A., Lee, S., Sheng, J., Li, F., Wong, S.T., Choi, H., El Rayes, T., Ryu, S., Troeger, J., et al. Epithelial-to-mesenchymal transition is not required for lung metastasis but contributes to chemoresistance. Nature 527 (2015), 472–476.
52. Galluzzi, L., Bravo-San Pedro, J.M., Levine, B., Green, D.R., Kroemer, G., Pharmacological modulation of autophagy: therapeutic potential and persisting obstacles. Nat. Rev. Drug Discov., 2017, 10.1038/nrd.2017.22.
53. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L., Kroemer, G., Immunological effects of conventional chemotherapy and targeted anticancer agents. Cancer Cell 28 (2015), 690–714.
54. Galluzzi, L., Buque, A., Kepp, O., Zitvogel, L., Kroemer, G., Immunogenic cell death in cancer and infectious disease. Nat. Rev. Immunol. 17 (2017), 97–111.
55. Galluzzi, L., Pietrocola, F., Bravo-San Pedro, J.M., Amaravadi, R.K., Baehrecke, E.H., Cecconi, F., Codogno, P., Debnath, J., Gewirtz, D.A., Karantza, V., et al. Autophagy in malignant transformation and cancer progression. EMBO J. 34 (2015), 856–880.
56. Gannon, P.O., Poisson, A.O., Delvoye, N., Lapointe, R., Mes-Masson, A.M., Saad, F., Characterization of the intra-prostatic immune cell infiltration in androgen-deprived prostate cancer patients. J. Immunol. Methods 348 (2009), 9–17.
57. Gao, H., Chakraborty, G., Zhang, Z., Akalay, I., Gadiya, M., Gao, Y., Sinha, S., Hu, J., Jiang, C., Akram, M., et al. Multi-organ site metastatic reactivation mediated by non-canonical discoidin domain receptor 1 signaling. Cell 166 (2016), 47–62.
58. Georgoudaki, A.M., Prokopec, K.E., Boura, V.F., Hellqvist, E., Sohn, S., Ostling, J., Dahan, R., Harris, R.A., Rantalainen, M., Klevebring, D., et al. Reprogramming tumor-associated macrophages by antibody targeting inhibits cancer progression and metastasis. Cell Rep. 15 (2016), 2000–2011.
59. Ghajar, C.M., Metastasis prevention by targeting the dormant niche. Nat. Rev. Cancer 15 (2015), 238–247.
60. Glasner, A., Ghadially, H., Gur, C., Stanietsky, N., Tsukerman, P., Enk, J., Mandelboim, O., Recognition and prevention of tumor metastasis by the NK receptor NKp46/NCR1. J. Immunol. 188 (2012), 2509–2515.
61. Gotthardt, D., Putz, E.M., Grundschober, E., Prchal-Murphy, M., Straka, E., Kudweis, P., Heller, G., Bago-Horvath, Z., Witalisz-Siepracka, A., Cumaraswamy, A.A., et al. STAT5 is a key regulator in NK cells and acts as a molecular switch from tumor surveillance to tumor promotion. Cancer Discov. 6 (2016), 414–429.
62. Gotthardt, D., Putz, E.M., Straka, E., Kudweis, P., Biaggio, M., Poli, V., Strobl, B., Muller, M., Sexl, V., Loss of STAT3 in murine NK cells enhances NK cell-dependent tumor surveillance. Blood 124 (2014), 2370–2379.
63. Gotwals, P., Cameron, S., Cipolletta, D., Cremasco, V., Crystal, A., Hewes, B., Mueller, B., Quaratino, S., Sabatos-Peyton, C., Petruzzelli, L., et al. Prospects for combining targeted and conventional cancer therapy with immunotherapy. Nat. Rev. Cancer 17 (2017), 286–301.
64. Guerra, N., Tan, Y.X., Joncker, N.T., Choy, A., Gallardo, F., Xiong, N., Knoblaugh, S., Cado, D., Greenberg, N.M., Raulet, D.H., NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity 28 (2008), 571–580.
65. Guillerey, C., Chow, M.T., Miles, K., Olver, S., Sceneay, J., Takeda, K., Moller, A., Smyth, M.J., Toll-like receptor 3 regulates NK cell responses to cytokines and controls experimental metastasis. Oncoimmunology, 4, 2015, e1027468.
66. Guillerey, C., Huntington, N.D., Smyth, M.J., Targeting natural killer cells in cancer immunotherapy. Nat. Immunol. 17 (2016), 1025–1036.
67. Han, J., Chu, J., Keung Chan, W., Zhang, J., Wang, Y., Cohen, J.B., Victor, A., Meisen, W.H., Kim, S.H., Grandi, P., et al. CAR-engineered NK cells targeting wild-type EGFR and EGFRvIII enhance killing of glioblastoma and patient-derived glioblastoma stem cells. Sci. Rep., 5, 2015, 11483.
68. Hanna, J., Goldman-Wohl, D., Hamani, Y., Avraham, I., Greenfield, C., Natanson-Yaron, S., Prus, D., Cohen-Daniel, L., Arnon, T.I., Manaster, I., et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat. Med. 12 (2006), 1065–1074.
69. Hanna, R.N., Cekic, C., Sag, D., Tacke, R., Thomas, G.D., Nowyhed, H., Herrley, E., Rasquinha, N., McArdle, S., Wu, R., et al. Patrolling monocytes control tumor metastasis to the lung. Science 350 (2015), 985–990.
70. Harper, K.L., Sosa, M.S., Entenberg, D., Hosseini, H., Cheung, J.F., Nobre, R., Avivar-Valderas, A., Nagi, C., Girnius, N., Davis, R.J., et al. Mechanism of early dissemination and metastasis in Her2+ mammary cancer. Nature, 2016, 10.1038/nature20609.
71. Hatfield, S.M., Kjaergaard, J., Lukashev, D., Schreiber, T.H., Belikoff, B., Abbott, R., Sethumadhavan, S., Philbrook, P., Ko, K., Cannici, R., et al. Immunological mechanisms of the antitumor effects of supplemental oxygenation. Sci. Transl. Med., 7, 2015, 277ra230.
72. Hay, C.M., Sult, E., Huang, Q., Mulgrew, K., Fuhrmann, S.R., McGlinchey, K.A., Hammond, S.A., Rothstein, R., Rios-Doria, J., Poon, E., et al. Targeting CD73 in the tumor microenvironment with MEDI9447. Oncoimmunology, 5, 2016, e1208875.
73. Hoshino, A., Costa-Silva, B., Shen, T.L., Rodrigues, G., Hashimoto, A., Tesic Mark, M., Molina, H., Kohsaka, S., Di Giannatale, A., Ceder, S., et al. Tumour exosome integrins determine organotropic metastasis. Nature 527 (2015), 329–335.
74. Hosseini, H., Obradovic, M.M., Hoffmann, M., Harper, K.L., Sosa, M.S., Werner-Klein, M., Nanduri, L.K., Werno, C., Ehrl, C., Maneck, M., et al. Early dissemination seeds metastasis in breast cancer. Nature, 2016, 10.1038/nature20785.
75. Iguchi-Manaka, A., Kai, H., Yamashita, Y., Shibata, K., Tahara-Hanaoka, S., Honda, S., Yasui, T., Kikutani, H., Shibuya, K., Shibuya, A., Accelerated tumor growth in mice deficient in DNAM-1 receptor. J. Exp. Med. 205 (2008), 2959–2964.
76. Ilander, M., Olsson-Stromberg, U., Schlums, H., Guilhot, J., Bruck, O., Lahteenmaki, H., Kasanen, T., Koskenvesa, P., Soderlund, S., Hoglund, M., et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31 (2017), 1108–1116.
77. Iraolagoitia, X.L., Spallanzani, R.G., Torres, N.I., Araya, R.E., Ziblat, A., Domaica, C.I., Sierra, J.M., Nunez, S.Y., Secchiari, F., Gajewski, T.F., et al. NK cells restrain spontaneous antitumor CD8+ T cell priming through PD-1/PD-L1 interactions with dendritic cells. J. Immunol. 197 (2016), 953–961.
78. Iribarren, K., Bloy, N., Buque, A., Cremer, I., Eggermont, A., Fridman, W.H., Fucikova, J., Galon, J., Spisek, R., Zitvogel, L., et al. Trial Watch: immunostimulation with Toll-like receptor agonists in cancer therapy. Oncoimmunology, 5, 2016, e1088631.
79. Ishigami, S., Natsugoe, S., Tokuda, K., Nakajo, A., Che, X., Iwashige, H., Aridome, K., Hokita, S., Aikou, T., Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 88 (2000), 577–583.
80. Ivashkiv, L.B., Donlin, L.T., Regulation of type I interferon responses. Nat. Rev. Immunol. 14 (2014), 36–49.
81. Junttila, T.T., Parsons, K., Olsson, C., Lu, Y., Xin, Y., Theriault, J., Crocker, L., Pabonan, O., Baginski, T., Meng, G., et al. Superior in vivo efficacy of afucosylated trastuzumab in the treatment of HER2-amplified breast cancer. Cancer Res. 70 (2010), 4481–4489.
82. Kang, Y., Siegel, P.M., Shu, W., Drobnjak, M., Kakonen, S.M., Cordon-Cardo, C., Guise, T.A., Massague, J., A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 3 (2003), 537–549.
83. Katlinski, K.V., Gui, J., Katlinskaya, Y.V., Ortiz, A., Chakraborty, R., Bhattacharya, S., Carbone, C.J., Beiting, D.P., Girondo, M.A., Peck, A.R., et al. Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment. Cancer Cell 31 (2017), 194–207.
84. Klein, C.A., Selection and adaptation during metastatic cancer progression. Nature 501 (2013), 365–372.
85. Knight, D.A., Ngiow, S.F., Li, M., Parmenter, T., Mok, S., Cass, A., Haynes, N.M., Kinross, K., Yagita, H., Koya, R.C., et al. Host immunity contributes to the anti-melanoma activity of BRAF inhibitors. J. Clin. Invest. 123 (2013), 1371–1381.
86. Kohrt, H.E., Thielens, A., Marabelle, A., Sagiv-Barfi, I., Sola, C., Chanuc, F., Fuseri, N., Bonnafous, C., Czerwinski, D., Rajapaksa, A., et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood 123 (2014), 678–686.
87. Kopp, H.G., Placke, T., Salih, H.R., Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Res. 69 (2009), 7775–7783.
88. Korde, N., Carlsten, M., Lee, M.J., Minter, A., Tan, E., Kwok, M., Manasanch, E., Bhutani, M., Tageja, N., Roschewski, M., et al. A phase II trial of pan-KIR2D blockade with IPH2101 in smoldering multiple myeloma. Haematologica 99 (2014), e81–83.
89. Lakshmikanth, T., Burke, S., Ali, T.H., Kimpfler, S., Ursini, F., Ruggeri, L., Capanni, M., Umansky, V., Paschen, A., Sucker, A., et al. NCRs and DNAM-1 mediate NK cell recognition and lysis of human and mouse melanoma cell lines in vitro and in vivo. J. Clin. Invest. 119 (2009), 1251–1263.
90. Lasek, W., Zagozdzon, R., Jakobisiak, M., Interleukin 12: still a promising candidate for tumor immunotherapy?. Cancer Immunol. Immunother. 63 (2014), 419–435.
91. Leong, J.W., Schneider, S.E., Sullivan, R.P., Parikh, B.A., Anthony, B.A., Singh, A., Jewell, B.A., Schappe, T., Wagner, J.A., Link, D.C., et al. PTEN regulates natural killer cell trafficking in vivo. Proc. Natl. Acad. Sci. USA 112 (2015), E700–E709.
92. Levental, K.R., Yu, H., Kass, L., Lakins, J.N., Egeblad, M., Erler, J.T., Fong, S.F., Csiszar, K., Giaccia, A., Weninger, W., et al. Matrix crosslinking forces tumor progression by enhancing integrin signaling. Cell 139 (2009), 891–906.
93. Levi, I., Amsalem, H., Nissan, A., Darash-Yahana, M., Peretz, T., Mandelboim, O., Rachmilewitz, J., Characterization of tumor infiltrating natural killer cell subset. Oncotarget 6 (2015), 13835–13843.
94. Levin, A.M., Bates, D.L., Ring, A.M., Krieg, C., Lin, J.T., Su, L., Moraga, I., Raeber, M.E., Bowman, G.R., Novick, P., et al. Exploiting a natural conformational switch to engineer an interleukin-2 'superkine'. Nature 484 (2012), 529–533.
95. Li, H., Han, Y., Guo, Q., Zhang, M., Cao, X., Cancer-expanded myeloid-derived suppressor cells induce anergy of NK cells through membrane-bound TGF-beta 1. J. Immunol. 182 (2009), 240–249.
96. Li, Y., Hofmann, M., Wang, Q., Teng, L., Chlewicki, L.K., Pircher, H., Mariuzza, R.A., Structure of natural killer cell receptor KLRG1 bound to E-cadherin reveals basis for MHC-independent missing self recognition. Immunity 31 (2009), 35–46.
97. Lima, P.D., Zhang, J., Dunk, C., Lye, S.J., Croy, B.A., Leukocyte driven-decidual angiogenesis in early pregnancy. Cell Mol. Immunol. 11 (2014), 522–537.
98. Liu, G., Atteridge, C.L., Wang, X., Lundgren, A.D., Wu, J.D., The membrane type matrix metalloproteinase MMP14 mediates constitutive shedding of MHC class I chain-related molecule A independent of A disintegrin and metalloproteinases. J. Immunol. 184 (2010), 3346–3350.
99. Liu, X., Shin, N., Koblish, H.K., Yang, G., Wang, Q., Wang, K., Leffet, L., Hansbury, M.J., Thomas, B., Rupar, M., et al. Selective inhibition of IDO1 effectively regulates mediators of antitumor immunity. Blood 115 (2010), 3520–3530.
100. Liu, Y., Gu, Y., Han, Y., Zhang, Q., Jiang, Z., Zhang, X., Huang, B., Xu, X., Zheng, J., Cao, X., Tumor exosomal RNAs promote lung pre-metastatic niche formation by activating alveolar epithelial TLR3 to recruit neutrophils. Cancer Cell 30 (2016), 243–256.
101. Lopez-Soto, A., Folgueras, A.R., Seto, E., Gonzalez, S., HDAC3 represses the expression of NKG2D ligands ULBPs in epithelial tumour cells: potential implications for the immunosurveillance of cancer. Oncogene 28 (2009), 2370–2382.
102. Lopez-Soto, A., Huergo-Zapico, L., Galvan, J.A., Rodrigo, L., de Herreros, A.G., Astudillo, A., Gonzalez, S., Epithelial-mesenchymal transition induces an antitumor immune response mediated by NKG2D receptor. J. Immunol. 190 (2013), 4408–4419.
103. Maecker, H.L., Yun, Z., Maecker, H.T., Giaccia, A.J., Epigenetic changes in tumor Fas levels determine immune escape and response to therapy. Cancer Cell 2 (2002), 139–148.
104. Malaise, M., Rovira, J., Renner, P., Eggenhofer, E., Sabet-Baktach, M., Lantow, M., Lang, S.A., Koehl, G.E., Farkas, S.A., Loss, M., et al. KLRG1+ NK cells protect T-bet-deficient mice from pulmonary metastatic colorectal carcinoma. J. Immunol. 192 (2014), 1954–1961.
105. Malladi, S., Macalinao, D.G., Jin, X., He, L., Basnet, H., Zou, Y., de Stanchina, E., Massague, J., Metastatic latency and immune evasion through autocrine inhibition of WNT. Cell 165 (2016), 45–60.
106. Martinet, L., Ferrari De Andrade, L., Guillerey, C., Lee, J.S., Liu, J., Souza-Fonseca-Guimaraes, F., Hutchinson, D.S., Kolesnik, T.B., Nicholson, S.E., Huntington, N.D., Smyth, M.J., DNAM-1 expression marks an alternative program of NK cell maturation. Cell Rep. 11 (2015), 85–97.
107. Massague, J., Obenauf, A.C., Metastatic colonization by circulating tumour cells. Nature 529 (2016), 298–306.
108. McCulloch, P., George, W.D., Warfarin inhibits metastasis of Mtln3 rat mammary carcinoma without affecting primary tumour growth. Br. J. Cancer 59 (1989), 179–183.
109. McDonald, O.G., Li, X., Saunders, T., Tryggvadottir, R., Mentch, S.J., Warmoes, M.O., Word, A.E., Carrer, A., Salz, T.H., Natsume, S., et al. Epigenomic reprogramming during pancreatic cancer progression links anabolic glucose metabolism to distant metastasis. Nat. Genet. 49 (2017), 367–376.
110. McNab, F., Mayer-Barber, K., Sher, A., Wack, A., O'Garra, A., Type I interferons in infectious disease. Nat. Rev. Immunol. 15 (2015), 87–103.
111. McWilliams, E.M., Mele, J.M., Cheney, C., Timmerman, E.A., Fiazuddin, F., Strattan, E.J., Mo, X., Byrd, J.C., Muthusamy, N., Awan, F.T., Therapeutic CD94/NKG2A blockade improves natural killer cell dysfunction in chronic lymphocytic leukemia. Oncoimmunology, 5, 2016, e1226720.
112. Menard, C., Blay, J.Y., Borg, C., Michiels, S., Ghiringhelli, F., Robert, C., Nonn, C., Chaput, N., Taieb, J., Delahaye, N.F., et al. Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients. Cancer Res. 69 (2009), 3563–3569.
113. Merzoug, L.B., Marie, S., Satoh-Takayama, N., Lesjean, S., Albanesi, M., Luche, H., Fehling, H.J., Di Santo, J.P., Vosshenrich, C.A., Conditional ablation of NKp46+ cells using a novel Ncr1(greenCre) mouse strain: NK cells are essential for protection against pulmonary B16 metastases. Eur. J. Immunol. 44 (2014), 3380–3391.
114. Messaoudene, M., Fregni, G., Fourmentraux-Neves, E., Chanal, J., Maubec, E., Mazouz-Dorval, S., Couturaud, B., Girod, A., Sastre-Garau, X., Albert, S., et al. Mature cytotoxic CD56(bright)/CD16(+) natural killer cells can infiltrate lymph nodes adjacent to metastatic melanoma. Cancer Res. 74 (2014), 81–92.
115. Mittal, D., Young, A., Stannard, K., Yong, M., Teng, M.W., Allard, B., Stagg, J., Smyth, M.J., Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor. Cancer Res. 74 (2014), 3652–3658.
116. Mlecnik, B., Bindea, G., Angell, H.K., Sasso, M.S., Obenauf, A.C., Fredriksen, T., Lafontaine, L., Bilocq, A.M., Kirilovsky, A., Tosolini, M., et al. Functional network pipeline reveals genetic determinants associated with in situ lymphocyte proliferation and survival of cancer patients. Sci. Transl. Med., 6, 2014, 228ra237.
117. Morandi, B., Mortara, L., Chiossone, L., Accolla, R.S., Mingari, M.C., Moretta, L., Moretta, A., Ferlazzo, G., Dendritic cell editing by activated natural killer cells results in a more protective cancer-specific immune response. PLoS One, 7, 2012, e39170.
118. Morel, A., Viaud, N., Bonnafous, C., Trichard, S., Joulin-Giet, A., Mizari, S., Grondin, G., Anceriz, N., Zhang, J., Jarzen, J., et al. Abstract 1491: IPH4301, an antibody targeting MICA and MICB exhibits potent cytotoxic activity and immunomodulatory properties for the treatment of cancer. Cancer Res., 76, 2016, 1491.
119. Morvan, M.G., Lanier, L.L., NK cells and cancer: you can teach innate cells new tricks. Nat. Rev. Cancer 16 (2016), 7–19.
120. Muntasell, A., Ochoa, M.C., Cordeiro, L., Berraondo, P., Lopez-Diaz de Cerio, A., Cabo, M., Lopez-Botet, M., Melero, I., Targeting NK-cell checkpoints for cancer immunotherapy. Curr. Opin. Immunol. 45 (2017), 73–81.
121. Nishikado, H., Mukai, K., Kawano, Y., Minegishi, Y., Karasuyama, H., NK cell-depleting anti-asialo GM1 antibody exhibits a lethal off-target effect on basophils in vivo. J. Immunol. 186 (2011), 5766–5771.
122. O'Sullivan, T., Saddawi-Konefka, R., Vermi, W., Koebel, C.M., Arthur, C., White, J.M., Uppaluri, R., Andrews, D.M., Ngiow, S.F., Teng, M.W., et al. Cancer immunoediting by the innate immune system in the absence of adaptive immunity. J. Exp. Med. 209 (2012), 1869–1882.
123. Padua, D., Zhang, X.H., Wang, Q., Nadal, C., Gerald, W.L., Gomis, R.R., Massague, J., TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. Cell 133 (2008), 66–77.
124. Paget, S., The distribution of secondary growths in cancer of the breast. 1889. Cancer Metastasis Rev. 8 (1989), 98–101.
125. Palumbo, J.S., Talmage, K.E., Massari, J.V., La Jeunesse, C.M., Flick, M.J., Kombrinck, K.W., Jirouskova, M., Degen, J.L., Platelets and fibrin(ogen) increase metastatic potential by impeding natural killer cell-mediated elimination of tumor cells. Blood 105 (2005), 178–185.
126. Paolino, M., Choidas, A., Wallner, S., Pranjic, B., Uribesalgo, I., Loeser, S., Jamieson, A.M., Langdon, W.Y., Ikeda, F., Fededa, J.P., et al. The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells. Nature 507 (2014), 508–512.
127. Paschen, A., Sucker, A., Hill, B., Moll, I., Zapatka, M., Nguyen, X.D., Sim, G.C., Gutmann, I., Hassel, J., Becker, J.C., et al. Differential clinical significance of individual NKG2D ligands in melanoma: soluble ULBP2 as an indicator of poor prognosis superior to S100B. Clin. Cancer Res. 15 (2009), 5208–5215.
128. Pasero, C., Gravis, G., Guerin, M., Granjeaud, S., Thomassin-Piana, J., Rocchi, P., Paciencia-Gros, M., Poizat, F., Bentobji, M., Azario-Cheillan, F., et al. Inherent and tumor-driven immune tolerance in the prostate microenvironment impairs natural killer cell antitumor activity. Cancer Res. 76 (2016), 2153–2165.
129. Pedersen, L., Idorn, M., Olofsson, G.H., Lauenborg, B., Nookaew, I., Hansen, R.H., Johannesen, H.H., Becker, J.C., Pedersen, K.S., Dethlefsen, C., et al. Voluntary running suppresses tumor growth through epinephrine- and IL-6-dependent NK cell mobilization and redistribution. Cell Metab. 23 (2016), 554–562.
130. Pedroza-Pacheco, I., Madrigal, A., Saudemont, A., Interaction between natural killer cells and regulatory T cells: perspectives for immunotherapy. Cell Mol Immunol 10 (2013), 222–229.
131. Peinado, H., Zhang, H., Matei, I.R., Costa-Silva, B., Hoshino, A., Rodrigues, G., Psaila, B., Kaplan, R.N., Bromberg, J.F., Kang, Y., et al. Pre-metastatic niches: organ-specific homes for metastases. Nat. Rev. Cancer 17 (2017), 302–317.
132. Placke, T., Orgel, M., Schaller, M., Jung, G., Rammensee, H.G., Kopp, H.G., Salih, H.R., Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Res. 72 (2012), 440–448.
133. Platonova, S., Cherfils-Vicini, J., Damotte, D., Crozet, L., Vieillard, V., Validire, P., Andre, P., Dieu-Nosjean, M.C., Alifano, M., Regnard, J.F., et al. Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res. 71 (2011), 5412–5422.
134. Polansky, J.K., Bahri, R., Divivier, M., Duitman, E.H., Vock, C., Goyeneche-Patino, D.A., Orinska, Z., Bulfone-Paus, S., High dose CD11c-driven IL15 is sufficient to drive NK cell maturation and anti-tumor activity in a trans-presentation independent manner. Sci. Rep., 6, 2016, 19699.
135. Putz, E.M., Gotthardt, D., Hoermann, G., Csiszar, A., Wirth, S., Berger, A., Straka, E., Rigler, D., Wallner, B., Jamieson, A.M., et al. CDK8-mediated STAT1-S727 phosphorylation restrains NK cell cytotoxicity and tumor surveillance. Cell Rep. 4 (2013), 437–444.
136. Putz, E.M., Guillerey, C., Kos, K., Stannard, K., Miles, K., Delconte, R.B., Takeda, K., Nicholson, S.E., Huntington, N.D., Smyth, M.J., Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis. Oncoimmunology, 6, 2017, e1267892.
137. Putz, E.M., Mayfosh, A., Kos, K., Barkauskas, D.S., Nakamura, K., Town, L., Goodall, K.J., Yee, D.Y., Poon, I.K.H., Baschuk, N., et al. NK cell heparanase controls tumor invasion and immune surveillance. J. Clin. Invest., 2017, 10.1172/JCI92958.
138. Rankin, E.B., Giaccia, A.J., Hypoxic control of metastasis. Science 352 (2016), 175–180.
139. Reddy, N., Hernandez-Ilizaliturri, F.J., Deeb, G., Roth, M., Vaughn, M., Knight, J., Wallace, P., Czuczman, M.S., Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br. J. Haematol. 140 (2008), 36–45.
140. Rhim, A.D., Mirek, E.T., Aiello, N.M., Maitra, A., Bailey, J.M., McAllister, F., Reichert, M., Beatty, G.L., Rustgi, A.K., Vonderheide, R.H., et al. EMT and dissemination precede pancreatic tumor formation. Cell 148 (2012), 349–361.
141. Ryan, J.J., Ketcham, A.S., Wexler, H., Reduced incidence of spontaneous metastases with long-term Coumadin therapy. Ann. Surg. 168 (1968), 163–168.
142. Sahin, U., Tureci, O., Schmitt, H., Cochlovius, B., Johannes, T., Schmits, R., Stenner, F., Luo, G., Schobert, I., Pfreundschuh, M., Human neoplasms elicit multiple specific immune responses in the autologous host. Proc. Natl. Acad. Sci. USA 92 (1995), 11810–11813.
143. Sathe, P., Delconte, R.B., Souza-Fonseca-Guimaraes, F., Seillet, C., Chopin, M., Vandenberg, C.J., Rankin, L.C., Mielke, L.A., Vikstrom, I., Kolesnik, T.B., et al. Innate immunodeficiency following genetic ablation of Mcl1 in natural killer cells. Nat. Commun., 5, 2014, 4539.
144. Sceneay, J., Chow, M.T., Chen, A., Halse, H.M., Wong, C.S., Andrews, D.M., Sloan, E.K., Parker, B.S., Bowtell, D.D., Smyth, M.J., Moller, A., Primary tumor hypoxia recruits CD11b+/Ly6Cmed/Ly6G+ immune suppressor cells and compromises NK cell cytotoxicity in the premetastatic niche. Cancer Res. 72 (2012), 3906–3911.
145. Schlecker, E., Fiegler, N., Arnold, A., Altevogt, P., Rose-John, S., Moldenhauer, G., Sucker, A., Paschen, A., von Strandmann, E.P., Textor, S., Cerwenka, A., Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res. 74 (2014), 3429–3440.
146. Schneider, W.M., Chevillotte, M.D., Rice, C.M., Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32 (2014), 513–545.
147. Schonberg, K., Rudolph, J., Vonnahme, M., Parampalli Yajnanarayana, S., Cornez, I., Hejazi, M., Manser, A.R., Uhrberg, M., Verbeek, W., Koschmieder, S., et al. JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res. 75 (2015), 2187–2199.
148. Seimetz, D., Lindhofer, H., Bokemeyer, C., Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy. Cancer Treat. Rev. 36 (2010), 458–467.
149. Semeraro, M., Galluzzi, L., Novel insights into the mechanism of action of lenalidomide. Oncoimmunology, 3, 2014, e28386.
150. Semeraro, M., Rusakiewicz, S., Zitvogel, L., Kroemer, G., Natural killer cell mediated immunosurveillance of pediatric neuroblastoma. Oncoimmunology, 4, 2015, e1042202.
151. Semeraro, M., Vacchelli, E., Eggermont, A., Galon, J., Zitvogel, L., Kroemer, G., Galluzzi, L., Trial watch: lenalidomide-based immunochemotherapy. Oncoimmunology, 2, 2013, e26494.
152. Senovilla, L., Vacchelli, E., Galon, J., Adjemian, S., Eggermont, A., Fridman, W.H., Sautes-Fridman, C., Ma, Y., Tartour, E., Zitvogel, L., et al. Trial watch: prognostic and predictive value of the immune infiltrate in cancer. Oncoimmunology 1 (2012), 1323–1343.
153. Shankaran, V., Ikeda, H., Bruce, A.T., White, J.M., Swanson, P.E., Old, L.J., Schreiber, R.D., IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 410 (2001), 1107–1111.
154. Sheppard, S., Guedes, J., Mroz, A., Zavitsanou, A.M., Kudo, H., Rothery, S.M., Angelopoulos, P., Goldin, R., Guerra, N., The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma. Nat. Commun., 8, 2017, 13930.
155. Shultz, L.D., Ishikawa, F., Greiner, D.L., Humanized mice in translational biomedical research. Nat. Rev. Immunol. 7 (2007), 118–130.
156. Sistigu, A., Yamazaki, T., Vacchelli, E., Chaba, K., Enot, D.P., Adam, J., Vitale, I., Goubar, A., Baracco, E.E., Remedios, C., et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat. Med. 20 (2014), 1301–1309.
157. Smyth, M.J., Crowe, N.Y., Godfrey, D.I., NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int. Immunol. 13 (2001), 459–463.
158. Smyth, M.J., Thia, K.Y., Cretney, E., Kelly, J.M., Snook, M.B., Forbes, C.A., Scalzo, A.A., Perforin is a major contributor to NK cell control of tumor metastasis. J. Immunol. 162 (1999), 6658–6662.
159. Smyth, M.J., Thia, K.Y., Street, S.E., Cretney, E., Trapani, J.A., Taniguchi, M., Kawano, T., Pelikan, S.B., Crowe, N.Y., Godfrey, D.I., Differential tumor surveillance by natural killer (NK) and NKT cells. J. Exp. Med. 191 (2000), 661–668.
160. Spiegel, A., Brooks, M.W., Houshyar, S., Reinhardt, F., Ardolino, M., Fessler, E., Chen, M.B., Krall, J.A., DeCock, J., Zervantonakis, I.K., et al. Neutrophils suppress intraluminal NK cell-mediated tumor cell clearance and enhance extravasation of disseminated carcinoma cells. Cancer Discov. 6 (2016), 630–649.
161. Spranger, S., Bao, R., Gajewski, T.F., Melanoma-intrinsic beta-catenin signalling prevents anti-tumour immunity. Nature 523 (2015), 231–235.
162. Stanietsky, N., Simic, H., Arapovic, J., Toporik, A., Levy, O., Novik, A., Levine, Z., Beiman, M., Dassa, L., Achdout, H., et al. The interaction of TIGIT with PVR and PVRL2 inhibits human NK cell cytotoxicity. Proc. Natl. Acad. Sci. USA 106 (2009), 17858–17863.
163. Steeg, P.S., Targeting metastasis. Nat. Rev. Cancer 16 (2016), 201–218.
164. Street, S.E., Cretney, E., Smyth, M.J., Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 97 (2001), 192–197.
165. Street, S.E., Hayakawa, Y., Zhan, Y., Lew, A.M., MacGregor, D., Jamieson, A.M., Diefenbach, A., Yagita, H., Godfrey, D.I., Smyth, M.J., Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J. Exp. Med. 199 (2004), 879–884.
166. Sun, X., Wu, Y., Gao, W., Enjyoji, K., Csizmadia, E., Muller, C.E., Murakami, T., Robson, S.C., CD39/ENTPD1 expression by CD4+Foxp3+ regulatory T cells promotes hepatic metastatic tumor growth in mice. Gastroenterology 139 (2010), 1030–1040.
167. Takeda, K., Hayakawa, Y., Smyth, M.J., Kayagaki, N., Yamaguchi, N., Kakuta, S., Iwakura, Y., Yagita, H., Okumura, K., Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells. Nat. Med. 7 (2001), 94–100.
168. Tallerico, R., Todaro, M., Di Franco, S., Maccalli, C., Garofalo, C., Sottile, R., Palmieri, C., Tirinato, L., Pangigadde, P.N., La Rocca, R., et al. Human NK cells selective targeting of colon cancer-initiating cells: a role for natural cytotoxicity receptors and MHC class I molecules. J. Immunol. 190 (2013), 2381–2390.
169. Tang, P.M., Zhou, S., Meng, X.M., Wang, Q.M., Li, C.J., Lian, G.Y., Huang, X.R., Tang, Y.J., Guan, X.Y., Yan, B.P., et al. Smad3 promotes cancer progression by inhibiting E4BP4-mediated NK cell development. Nat. Commun., 8, 2017, 14677.
170. Thienpont, B., Steinbacher, J., Zhao, H., D'Anna, F., Kuchnio, A., Ploumakis, A., Ghesquiere, B., Van Dyck, L., Boeckx, B., Schoonjans, L., et al. Tumour hypoxia causes DNA hypermethylation by reducing TET activity. Nature 537 (2016), 63–68.
171. Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L.E., Zhang, X., Putluri, N., et al. Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming. Nature 544 (2017), 250–254.
172. Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
173. Tu, T.C., Brown, N.K., Kim, T.J., Wroblewska, J., Yang, X., Guo, X., Lee, S.H., Kumar, V., Lee, K.M., Fu, Y.X., CD160 is essential for NK-mediated IFN-gamma production. J. Exp. Med. 212 (2015), 415–429.
174. Turajlic, S., Swanton, C., Metastasis as an evolutionary process. Science 352 (2016), 169–175.
175. Vacca, P., Cantoni, C., Vitale, M., Prato, C., Canegallo, F., Fenoglio, D., Ragni, N., Moretta, L., Mingari, M.C., Crosstalk between decidual NK and CD14+ myelomonocytic cells results in induction of Tregs and immunosuppression. Proc. Natl. Acad. Sci. USA 107 (2010), 11918–11923.
176. Vacchelli, E., Aranda, F., Bloy, N., Buque, A., Cremer, I., Eggermont, A., Fridman, W.H., Fucikova, J., Galon, J., Spisek, R., et al. Trial Watch-Immunostimulation with cytokines in cancer therapy. Oncoimmunology, 5, 2016, e1115942.
177. Vadrevu, S.K., Chintala, N.K., Sharma, S.K., Sharma, P., Cleveland, C., Riediger, L., Manne, S., Fairlie, D.P., Gorczyca, W., Almanza, O., et al. Complement c5a receptor facilitates cancer metastasis by altering T-cell responses in the metastatic niche. Cancer Res. 74 (2014), 3454–3465.
178. van der Weyden, L., Arends, M.J., Campbell, A.D., Bald, T., Wardle-Jones, H., Griggs, N., Velasco-Herrera, M.D., Tuting, T., Sansom, O.J., Karp, N.A., et al. Genome-wide in vivo screen identifies novel host regulators of metastatic colonization. Nature 541 (2017), 233–236.
179. van Helden, M.J., Goossens, S., Daussy, C., Mathieu, A.L., Faure, F., Marcais, A., Vandamme, N., Farla, N., Mayol, K., Viel, S., et al. Terminal NK cell maturation is controlled by concerted actions of T-bet and Zeb2 and is essential for melanoma rejection. J. Exp. Med. 212 (2015), 2015–2025.
180. Vanpouille-Box, C., Alard, A., Aryankalayil, M.J., Sarfraz, Y., Diamond, J.M., Schneider, R.J., Inghirami, G., Coleman, C.N., Formenti, S.C., Demaria, S., DNA exonuclease Trex1 regulates radiotherapy-induced tumor immunogenicity. Nat. Commun., 8, 2017, 15618.
181. Vences-Catalan, F., Rajapaksa, R., Srivastava, M.K., Marabelle, A., Kuo, C.C., Levy, R., Levy, S., Tetraspanin CD81 promotes tumor growth and metastasis by modulating the functions of T regulatory and myeloid-derived suppressor cells. Cancer Res. 75 (2015), 4517–4526.
182. Viel, S., Marcais, A., Guimaraes, F.S., Loftus, R., Rabilloud, J., Grau, M., Degouve, S., Djebali, S., Sanlaville, A., Charrier, E., et al. TGF-beta inhibits the activation and functions of NK cells by repressing the mTOR pathway. Sci. Signal., 9, 2016, ra19.
183. Waggoner, S.N., Cornberg, M., Selin, L.K., Welsh, R.M., Natural killer cells act as rheostats modulating antiviral T cells. Nature 481 (2011), 394–398.
184. Waggoner, S.N., Taniguchi, R.T., Mathew, P.A., Kumar, V., Welsh, R.M., Absence of mouse 2B4 promotes NK cell-mediated killing of activated CD8+ T cells, leading to prolonged viral persistence and altered pathogenesis. J. Clin. Invest. 120 (2010), 1925–1938.
185. Walker, J.A., Barlow, J.L., McKenzie, A.N., Innate lymphoid cells–how did we miss them?. Nat. Rev. Immunol. 13 (2013), 75–87.
186. Wculek, S.K., Malanchi, I., Neutrophils support lung colonization of metastasis-initiating breast cancer cells. Nature 528 (2015), 413–417.
187. Weiner, L.M., Surana, R., Wang, S., Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10 (2010), 317–327.
188. Welch, H.G., Prorok, P.C., O'Malley, A.J., Kramer, B.S., Breast-cancer tumor size, overdiagnosis, and mammography screening effectiveness. N. Engl. J. Med. 375 (2016), 1438–1447.
189. Werneck, M.B., Lugo-Villarino, G., Hwang, E.S., Cantor, H., Glimcher, L.H., T-bet plays a key role in NK-mediated control of melanoma metastatic disease. J. Immunol. 180 (2008), 8004–8010.
190. Woloshin, S., Schwartz, L.M., Black, W.C., Kramer, B.S., Cancer screening campaigns–getting past uninformative persuasion. N. Engl. J. Med. 367 (2012), 1677–1679.
191. Wu, L., Adams, M., Carter, T., Chen, R., Muller, G., Stirling, D., Schafer, P., Bartlett, J.B., Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin. Cancer Res. 14 (2008), 4650–4657.
192. Yamaguchi, K., Chikumi, H., Shimizu, A., Takata, M., Kinoshita, N., Hashimoto, K., Nakamoto, M., Matsunaga, S., Kurai, J., Miyake, N., et al. Diagnostic and prognostic impact of serum-soluble UL16-binding protein 2 in lung cancer patients. Cancer Sci. 103 (2012), 1405–1413.
193. Young, A., Mittal, D., Stagg, J., Smyth, M.J., Targeting cancer-derived adenosine: new therapeutic approaches. Cancer Discov. 4 (2014), 879–888.
194. Young, A., Ngiow, S.F., Barkauskas, D.S., Sult, E., Hay, C., Blake, S.J., Huang, Q., Liu, J., Takeda, K., Teng, M.W., et al. Co-inhibition of CD73 and A2AR adenosine signaling improves anti-tumor immune responses. Cancer Cell 30 (2016), 391–403.
195. Yu, M., Ting, D.T., Stott, S.L., Wittner, B.S., Ozsolak, F., Paul, S., Ciciliano, J.C., Smas, M.E., Winokur, D., Gilman, A.J., et al. RNA sequencing of pancreatic circulating tumour cells implicates WNT signalling in metastasis. Nature 487 (2012), 510–513.
196. Zaynagetdinov, R., Sherrill, T.P., Gleaves, L.A., McLoed, A.G., Saxon, J.A., Habermann, A.C., Connelly, L., Dulek, D., Peebles, R.S. Jr., Fingleton, B., et al. Interleukin-5 facilitates lung metastasis by modulating the immune microenvironment. Cancer Res. 75 (2015), 1624–1634.
197. Zhang, J., Basher, F., Wu, J.D., NKG2D ligands in tumor immunity: two sides of a coin. Front. Immunol., 6, 2015, 97.
198. Zhang, L., Zhang, S., Yao, J., Lowery, F.J., Zhang, Q., Huang, W.C., Li, P., Li, M., Wang, X., Zhang, C., et al. Microenvironment-induced PTEN loss by exosomal microRNA primes brain metastasis outgrowth. Nature 527 (2015), 100–104.
199. Zhang, X.H., Wang, Q., Gerald, W., Hudis, C.A., Norton, L., Smid, M., Foekens, J.A., Massague, J., Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell 16 (2009), 67–78.
200. Zheng, X., Carstens, J.L., Kim, J., Scheible, M., Kaye, J., Sugimoto, H., Wu, C.C., LeBleu, V.S., Kalluri, R., Epithelial-to-mesenchymal transition is dispensable for metastasis but induces chemoresistance in pancreatic cancer. Nature 527 (2015), 525–530.
201. Zhu, Y., Paniccia, A., Schulick, A.C., Chen, W., Koenig, M.R., Byers, J.T., Yao, S., Bevers, S., Edil, B.H., Identification of CD112R as a novel checkpoint for human T cells. J. Exp. Med. 213 (2016), 167–176.
202. Zingoni, A., Cecere, F., Vulpis, E., Fionda, C., Molfetta, R., Soriani, A., Petrucci, M.T., Ricciardi, M.R., Fuerst, D., Amendola, M.G., et al. Genotoxic stress induces senescence-associated ADAM10-dependent release of NKG2D MIC ligands in multiple myeloma cells. J. Immunol. 195 (2015), 736–748.
203. Zitvogel, L., Galluzzi, L., Kepp, O., Smyth, M.J., Kroemer, G., Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15 (2015), 405–414.